Medications as risk factors of stevens-johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis

Pediatrics

Volumn 123, Issue 2, 2009, Pages

  Levi, Natacha ^a   Bastuji Garin, Sylvie ^b   Mockenhaupt, Maja ^e   Roujeau, Jean Claude ^c,d   Flahault, Antoine ^f   Kelly, Judith P ^g   Martin, Elvira ^d   Kaufman, David W ^g   Maison, Patrick ^a,d,h  

^a Service de Pharmacologie Clinique   (Germany)

^b Service de Santé Publique   (Germany)

^c Service de dermatologie   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY OF FREIBURG   (Germany)

^f EHESP SCHOOL OF PUBLIC HEALTH   (France)

^g BOSTON UNIVERSITY   (United States)

^h INSERM   (France)

Author keywords

Drugs; Medication risk factors; Meta analysis; Pharmacoepidemiology

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID DERIVATIVE; IBUPROFEN; KETOPROFEN; LAMOTRIGINE; MACROLIDE; MUCOLYTIC AGENT; NEVIRAPINE; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TIAPROFENIC ACID; UNINDEXED DRUG; VACCINE; VALPROIC ACID; VITAMIN; DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; AUSTRIA; CONTROLLED STUDY; FEMALE; FRANCE; GERMANY; HUMAN; ISRAEL; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PORTUGAL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHILD; INFANT; PRESCHOOL CHILD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; INFANT; MALE; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; STEVENS-JOHNSON SYNDROME;

EID: 61549110213     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1923     Document Type: Article

References (60)

1. Stevens-Johnson syndrome, toxic epidermal necrolysis, Lyell syndrome, severe cutaneous adverse reaction, children,
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96
4. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int. 2002;14(4):143-150
5. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160-1165
6. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126(1):37-42
7. Binaghi M, Koso M, Roujeau JC, Coscas G. Ocular complications of Lyell's syndrome: recent concepts apropos of 26 cases [in French]. J Fr Ophtalmol. 1985;8(3):239-243
8. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990 -1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769-773
9. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987;123(9):1166-1170
10. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28S-30S
11. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens- Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8): 1019 -1024
12. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Vi- boud C, Roujeau JC. Nevirapine and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. Aids. 2001; 15(14):1843-1848
13. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7): 1134-1138
14. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600 -1607
15. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet. 1999;353(9171): 2190-2194
16. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug- induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26(4):567-574
17. Coopman SA, Stern RS. Cutaneous drug reactions in human immunodeficiency virus infection. Arch Dermatol. 1991;127(5): 714-717
18. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with mycoplasma pneu- moniae infection. Eur J Clin Microbiol Infect Dis. 1995;14(6): 558 -559
19. Meseguer MA, de Rafael L, Vidal ML. Stevens-Johnson syndrome with isolation of mycoplasma pneumoniae from skin lesions. Eur J Clin Microbiol. 1986;5(2):167-168
20. Stutman HR. Stevens-Johnson syndrome and mycoplasma pneumoniae: evidence for cutaneous infection. J Pediatr. 1987; 111(6 pt 1):845-847
21. Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007; 119(4). Available at: www.pediatrics.org/cgi/content/ full/119/4/e1002
22. Ruggiero A, Buonuomo PS, Maurizi P, Cefalo MP, Corsello M, Riccardi R. Stevens-Johnson syndrome in children receiving phenobarbital therapy and cranial radiotherapy. J Neurooncol. 2007;85(2):213-215
23. Maiche A, Teerenhovi L. Stevens-Johnson syndrome in patients receiving radiation therapy. Lancet. 1985;2(8445):45
24. Burge SM, Dawber RP. Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythem- atosus. J Am Acad Dermatol. 1985;13(4):665-666
25. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-299
26. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990; 23(6 pt 1):1039-1058
27. Hawk RJ, Storer JS, Daum RS. Toxic epidermal necrolysis in a 6-week-old infant. Pediatr Dermatol. 1985;2(3):197-200
28. Teillac D, Marsol P, Richard P, et al. Toxic epidermal necrolysis in children (Lyell's syndrome): apropos of 18 cases [in French]. Arch Fr Pediatr. 1987;44(8):583-587
29. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44
30. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30(10):2234-2240
31. Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37(3-4):256 -266
32. Schlesselman JJ. Case Control Studies: Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982
33. Hirji K, Tsiatis AA, Mehta CR. Median unbiased estimation for binary data. Am Stat. 1989;43(1):7-11
34. Horwitz RI, Feinstein AR. The problem of "protopathic bias" in case-control studies. Am J Med. 1980;68(2):255-258
35. Hansen RC. Staphylococcal scalded skin syndrome, toxic shock syndrome, and kawasaki disease. Pediatr Clin North Am. 1983; 30(3):533-544
36. Snyder RA, Elias PM. Toxic epidermal necrolysis and staphy- lococcal scaled syndrome. Dermatol Clin. 1983;1:235-248
37. Maison P, Guillemot D, Vauzelle-Kervroedan F, et al. Trends in aspirin, paracetamol and non-steroidal anti-inflammatory drug use in children between 1981 and 1992 in France. Eur J Clin Pharmacol. 1998;54(8):659-664
38. Sanz E, Hernandez MA, Ratchina S, et al. Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). Eur J Clin Pharmacol. 2004;60(2):127-134
39. Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol. 1967;79(12):662-671
40. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing. 1993;22(6):450-456
41. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. Scorten: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149 -153
42. 41.Golden HE. Stevens-Johnson syndrome associated with herpes simplex virus. Arch Intern Med. 1993;153(11):1396
43. Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmaco- genetics. 1995;5(4):255-258
44. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. 2002;25(13):965-972
45. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine- associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985-991
46. Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 2005;35(3):188-190
47. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics. 2002;109(1):74-78
48. Lam NS, Yang YH, Wang LC, Lin YT, Chiang BL. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect. 2004;37(6):366-370
49. Neuman M, Nicar M. Apoptosis in ibuprofen-induced Stevens- Johnson syndrome. Transl Res. 2007;149(5):254-259
50. Dore J, Salisbury RE. Morbidity and mortality of mucocutane- ous diseases in the pediatric population at a tertiary care center. J Burn Care Res. 2007;28(6):865-870
51. Kaufman D, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia: The International Agranulo- cytosis and Aplastic Anemia Study. New York, NY: Oxford University Press; 1991
52. Bygum A, Gregersen JW, Buus SK. Acetaminophen-induced toxic epidermal necrolysis in a child. Pediatr Dermatol. 2004;21(3):236 -238
53. Halevi A, Ben-Amitai D, Garty BZ. Toxic epidermal necrolysis associated with acetaminophen ingestion. Ann Pharmacother. 2000;34(1):32-34
54. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20(2):219 -223
55. Dobrosavljevic D, Milinkovic MV, Nikolic MM. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol. 1999;13(1):59 -61
56. Shoss RG, Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol. 1974;110(5):766 -770
57. Lonjou C, Borot N, Sekula P, et al. A European study of hla-b in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99 -107
58. 57.Lonjou C, Thomas L, Borot N, et al. A marker for Stevens- Johnson syndrome: ethnicity matters. Pharmacogenomics J.2006;6(4):265-268
59. Hunkeler EM, Fireman B, Lee J, et al. Trends in use of anti- depressants, lithium, and anticonvulsants in Kaiser Perma- nente-insured youths, 1994-2003. J Child Adolesc Psychophar- macol. 2005;15(1):26-37
60. Slone Epidemiology Center. Patterns of medication use in the United States: 2006. Available at: www.Bu.Edu/slone/ slonesurvey/annualrpt/ slonesurveywebreport2006.pdf. Accessed December 15, 2008